Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01685008 · ClinicalTrials.gov registry record · Phase 2

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

A Phase 2 study of Non-Hodgkin Lymphoma, sponsored by MorphoSys.

Completed
Registry status
Phase 2
Development phase
92
Enrollment target
20
Study locations

NCT01685008 is a Phase 2 study of Non-Hodgkin Lymphoma that has completed, run by MorphoSys. The registered enrollment target is 92 participants, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01685008, a Phase 2 study of Non-Hodgkin Lymphoma, has completed, sponsored by MorphoSys.

COMPLETED
Registry status
Phase 2
Development phase
92 participants
Enrollment target
20
Study locations

Study Summary

This is an open-label, multicenter study to characterize the safety and efficacy of the human anti-CD19 antibody MOR00208 in adult patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) who have received at least 1 prior therapy containing rituximab (at least once).

Conditions Studied

Non-Hodgkin Lymphoma

Interventions

  • DRUG MOR00208 (formerly Xmab 5574)

Study Locations (20)

Other

  • MorphoSys Research Site - Brussels
  • MorphoSys Research Site - Edegem
  • MorphoSys Research Site - Berlin
  • MorphoSys Research Site - Mainz
  • Morphosys Research Site - Ulm
  • Morphosys Research Site - Budapest
  • Morphosys Research Site - Debrecen
  • MorphoSys Research Site - Bologna
  • MorphoSys Research Site - Florence
  • Morphosys - Genova
  • Morphosys Research Site - Modena
  • Morphosys Research Site - Novara
  • MorphoSys Research Site - Chorzów
  • Morphosys Research Site - Krakow
  • Morphosys Research Site - Lódz
  • MorphoSys Research Site - Słupsk

Connecticut

  • MorphoSys Research Site - Norwalk

New Jersey

  • MorphoSys Research Site - Hackensack

Ohio

  • Morphosys Research Site - Columbus

Texas

  • Morphosys Research Site - Lubbock

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2013-04-23
Est. Completion 2022-04-06
Phase Phase 2

Sponsor

MorphoSys

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01685008

The ClinicalTrials.gov registry entry for NCT01685008 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 151-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target (39% lower). The listed sponsor is MorphoSys, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which MOR00208 (formerly Xmab 5574) is the first listed.

NCT01685008 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, Connecticut, New Jersey.

Frequently Asked Questions

What is clinical trial NCT01685008 about?

NCT01685008 is a clinical study titled "Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)". This is an open-label, multicenter study to characterize the safety and efficacy of the human anti-CD19 antibody MOR00208 in adult patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) who have received at least 1 prior therapy containing rituximab (at least once).

What is the current status of trial NCT01685008?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2013-04-23. Estimated completion is 2022-04-06.

What conditions does trial NCT01685008 study?

This clinical trial studies the following conditions: Non-Hodgkin Lymphoma.

What interventions are being tested in trial NCT01685008?

The interventions under investigation include: MOR00208 (formerly Xmab 5574) (DRUG).

Who is sponsoring clinical trial NCT01685008?

This trial is sponsored by MorphoSys, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01685008 being conducted?

This trial has 20 study locations across Connecticut, New Jersey, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Hodgkin Lymphoma

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.